In some clinical trials, the incidence rate of PD-1/PD-L1-related peripheral edema was obviously higher than the placebo or observation group (Table 1),[40,42] while it was lower than Sunitinib.[39] However, since there were too few relevant clinical trials to conduct a meta-analysis, the conclusions were still controversial and needed to be further verified.[39,40,42]. The gene discussed is CD274; the disease is Peripheral edema.